BRAF is an inclusion eligibility criterion in 1 clinical trial for colon adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and colon adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for colon adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and colon adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for colon adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and colon adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for colon adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and colon adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 3 clinical trials for colon adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3CA status and colon adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 3 (2 open) [3].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for colon adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and colon adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].

POLE is an inclusion eligibility criterion in 1 clinical trial for colon adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and colon adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [3].